Web: | mayocliniclabs.com |
---|---|
Email: | mcl@mayo.edu |
Telephone: | 800-533-1710 |
International: | +1 855-379-3115 |
Values are valid only on day of printing. |
Detection of coronavirus disease 2019 (COVID-19) illness due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Recommended only for patients who meet current clinical and/or epidemiologic criteria defined by federal, state, or local public health directives: www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html
This test provides qualitative detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA from upper respiratory tract specimens from patients under investigation (PUI) for coronavirus disease 2019 (COVID-19).
Sequence analyses have predicted that this test will detect the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) variants.
Fact sheets for this emergency use authorized (EUA) assay can be found at the following links:
For health care providers: www.fda.gov/media/136047/download
For patients: www.fda.gov/media/136048/download
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
TATCH | TAT <=2 days additional charge | No | No |
In response to the new Centers for Medicare and Medicaid Services (CMS) payment strategy for coronavirus disease 2019 (COVID-19) diagnostic testing, a bill-only code will be added for orders that meet the new CMS turn-around-time requirement. For additional information refer to www.cms.gov/newsroom/press-releases/cms-changes-medicare-payment-support-faster-covid-19-diagnostic-testing.
Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR)